Eclipse (OPH1003 212165): A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTATM (ANTI PDGF-B PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH LUCENTIS® COMPARED TO LUCENTIS® MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION